

CNS SPECTRUMS®

The International Journal of Neuropsychiatric Medicine



ACADEMIC SUPPLEMENT

Anxiety and Depression in the Elderly: Implications for Diagnosis and Treatment

Introduction

D.L. Dunner

Treatment Considerations for Anxiety in the Elderly

*E.J. Lenze, B.G. Pollock, M.K. Shear, B.H. Mulsant,
A. Bharucha, and C.F. Reynolds III*

Treatment Considerations for Depression in the Elderly

D.L. Dunner

Medically Unexplained Physical Symptoms: Toward an Alternative Paradigm for Diagnosis and Treatment

C.A. Ballas and J.P. Staab

Achieving Long-Term Optimal Outcomes in Geriatric Depression and Anxiety

*B.H. Mulsant, E. Whyte, E.J. Lenze, F. Lotrich,
J.F. Karp, B.G. Pollock, and C.F. Reynolds III*

Quality of Life in Geriatric Patients with Mood and Anxiety Disorders

R.E. Maddux, K.K. Delrahim, and M.H. Rapaport

Adherence to Treatment for Geriatric Depression and Anxiety

J.L. Wetherell and J. Unützer

Dr. Ballas is instructor in the Department of Psychiatry at the Hospital of the University of Pennsylvania in Philadelphia. He is on the Speaker's Bureau of AstraZeneca, Eli Lilly, Pfizer, and Wyeth.

Dr. Bharucha is assistant professor of psychiatry in the Department of Psychiatry at the University of Pittsburgh School of Medicine in Pennsylvania. He is on the Speaker's Bureau of Forest.

Ms. Delrahim is a research associate in the Department of Psychiatry at Cedars Sinai Medical Center in Los Angeles, California. She reports no affiliation with or financial interest in a commercial organization that might pose a conflict of interest.

Dr. Dunner is director of the Center for Anxiety and Depression and professor in the Department of Psychiatry and Behavioral Sciences at the University of Washington in Seattle. Dr. Dunner is a consultant to Bristol-Myers Squibb, Corcept, Cypress, Eli Lilly, GlaxoSmithKline, Novartis, Otsuka, Pfizer, and Wyeth; is on the Speaker's Bureau of Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Organon, Pfizer, and Wyeth; and receives research support from Cyberonics, Eli Lilly, GlaxoSmithKline, Janssen, Merck, Pfizer, and Wyeth.

Dr. Karp is a research fellow in the Department of Psychiatry at the University of Pittsburgh School of Medicine in Pennsylvania. He reports no affiliation with or financial interest in a commercial organization that might pose a conflict of interest.

Dr. Lenze is assistant professor of psychiatry in the Department of Psychiatry at the University of Pittsburgh School of Medicine in Pennsylvania. He has received grant support from Forest, Janssen, and Pfizer.

Dr. Lotrich is a research fellow in the Department of Psychiatry at the University of Pittsburgh School of Medicine in Pennsylvania. He reports no affiliation with or financial interest in a commercial organization that might pose a conflict of interest.

Ms. Maddux is a research associate in the Department of Psychiatry at Cedars Sinai Medical Center in Los Angeles, California. She reports no affiliation with or financial interest in a commercial organization that might pose a conflict of interest.

Dr. Mulsant is associate professor of psychiatry in the Department of Psychiatry at the University of Pittsburgh School of Medicine in Pennsylvania. He is a consultant to AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Janssen, and Pfizer; is on the Speaker's Bureau of AstraZeneca, Forest, GlaxoSmithKline, Janssen, and Pfizer; and has received honoraria or grant support from AstraZeneca, Corcept, Eisai, Eli Lilly, Forest, GlaxoSmithKline, Janssen, Lundbeck, and Pfizer.

Dr. Pollock is professor of psychiatry and pharmacology in the Department of Psychiatry at the University of Pittsburgh School of Medicine in Pennsylvania. He is a consultant to AstraZeneca, Forest, GlaxoSmithKline, Janssen, NPS Pharmaceuticals, and Organon; is on the Speaker's Bureau of Forest, and has received grant/research support from Forest, GlaxoSmithKline, and Janssen.

Dr. Rapaport is chair of the Department of Psychiatry at Cedars Sinai Medical Center and vice chair of the Department of Psychiatry at the University of Los Angeles, California. He has received research support or honoraria from Abbott, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Novartis, Pfizer, Pharmacia and Upjohn, Robert Wood Johnson, Sanofi-Synthelabo, and Wyeth; has served as a consultant to Eli Lilly, Forest, Janssen, Pfizer, Pharmacia & Upjohn, and Sanofi-Synthelabo; and has been on the Speaker's Bureau of Eli Lilly, Forest, Janssen, Pfizer, Pharmacia & Upjohn, and GlaxoSmithKline.

Dr. Reynolds is professor of psychiatry, neurology, and neuroscience, and director of the Intervention Research Center in Late-Life Mood Disorders, in the Department of Psychiatry at the University of Pittsburgh School of Medicine in Pennsylvania. He is on the Speaker's Bureau of and has received research support from Forest and GlaxoSmithKline.

Dr. Shear is professor of psychiatry in the Department of Psychiatry at the University of Pittsburgh School of Medicine in Pennsylvania. She is a consultant to and on the Speaker's Bureau of GlaxoSmithKline and Pfizer; and has received research grants from Forest and Pfizer.

Dr. Staab is assistant professor of psychiatry in the Departments of Psychiatry and Otorhinolaryngology – Head and Neck Surgery, and director of Psychiatric Services at the Hospital of the University of Pennsylvania in Philadelphia. He is a consultant to Janssen and Pfizer; on the Speaker's Bureau of Forest, Janssen, and Pfizer; and has received research grants from Pfizer.

Dr. Unützer is professor and vice chair of psychiatry at the University of Washington School of Medicine in Seattle. He reports no affiliation with or financial interest in a commercial organization that might pose a conflict of interest.

Dr. Wetherell is assistant professor in residence in the Department of Psychiatry at the University of California, San Diego, and staff psychologist in the Veteran's Affairs San Diego Healthcare System. She reports no affiliation with or financial interest in a commercial organization that might pose a conflict of interest.

Dr. Whyte is assistant professor of psychiatry in the Department of Psychiatry at the University of Pittsburgh School of Medicine in Pennsylvania. She has received grant support from Janssen and Pfizer.

Disclaimer

This academic supplement is supported via an unrestricted educational grant from GlaxoSmithKline. Sponsorship of this review does not imply the sponsor's agreement with the views expressed herein.

Although every effort has been made to ensure that drug doses and other information are presented accurately in this publication, the ultimate responsibility rests with the prescribing physician. Neither the publisher, the sponsor, nor the authors can be held responsible for errors or for any consequences arising from the use of information contained herein. Readers are strongly urged to consult any relevant primary literature. No claims or endorsements are made for any drug or compound currently under clinical investigation.

Copyright ©2003, MBL Communications, Inc.

333 Hudson St., 7th Floor, New York, NY 10013.

Printed in the USA. All rights reserved, including the right of reproduction, in whole or in part, in any form.

CNS SPECTRUMS®

The International Journal of Neuropsychiatric Medicine

EDITOR

Jack M. Gorman, MD
Mount Sinai School of Medicine
New York, NY

ASSOCIATE AND FOUNDING EDITOR

Eric Hollander, MD
Mount Sinai School of Medicine
New York, NY

INTERNATIONAL EDITOR

Joseph Zohar, MD
Chaim Sheba Medical Center
Tel-Hashomer, Israel

ASSOCIATE INTERNATIONAL EDITORS

EUROPE

Donatella Marazziti, MD
University of Pisa
Pisa, Italy

MID-ATLANTIC

Dan J. Stein, MD, PhD
University of Stellenbosch
Tygerberg, South Africa

FAR EAST

Shigeto Yamawaki, MD, PhD
Hiroshima University School
of Medicine
Hiroshima, Japan

MEDICAL REVIEWER

David L. Ginsberg, MD
New York University Medical Center
New York, NY

BOARD OF ADVISORS

NEUROLOGISTS

Mitchell F. Brin, MD
University of California, Irvine
Irvine, CA

Jeffrey L. Cummings, MD
University of California, Los Angeles
Los Angeles, CA

Jerome Engel, Jr., MD, PhD

University of California, Los Angeles
Los Angeles, CA

Mark S. George, MD

Medical University of South Carolina
Charleston, SC

Richard B. Lipton, MD

Albert Einstein College of Medicine
Bronx, NY

C. Warren Olanow, MD, FRCPC

Mount Sinai School of Medicine
New York, NY

Steven George Pavlakis, MD

Maimonides Medical Center
Brooklyn, NY

Stephen D. Silberstein, MD, FACP

Thomas Jefferson University
Philadelphia, PA

Michael Trimble, MD, FRCP, FRPsych

National Hospital for Neurology
and Neurosurgery
London, United Kingdom

PSYCHIATRISTS

Margaret Altemus, MD

Cornell University Medical College
New York, NY

Dennis S. Charney, MD

National Institute of Mental Health
Bethesda, MD

Dwight L. Evans, MD

University of Pennsylvania
Philadelphia, PA

Siegfried Kasper, MD

University of Vienna
Vienna, Austria

Martin B. Keller, MD

Brown Medical School
Providence, RI

Lorin M. Koran, MD

Stanford University School of Medicine
Stanford, CA

Yves Lecrubier, MD

Hôpital de la Salpêtrière
Paris, France

Herbert Y. Meltzer, MD

Vanderbilt University Medical Center
Nashville, TN

Stuart A. Montgomery, MD

St. Mary's Hospital Medical School
London, United Kingdom

Charles B. Nemeroff, MD, PhD

Emory University School of Medicine
Atlanta, GA

Humberto Nicolini, MD, PhD

National Mexican Institute of Psychiatry
Mexico City, Mexico

Stefano Pallanti, MD, PhD

University of Florence
Florence, Italy

Katharine Phillips, MD

Brown Medical School
Providence, RI

Harold A. Pincus, MD

Western Psychiatric Institute & Clinic
RAND-University of Pittsburgh Health
Institute, Pittsburgh, PA

Scott L. Rauch, MD

Massachusetts General Hospital
Charlestown, MA

Alan F. Schatzberg, MD

Stanford University School of Medicine
Stanford, CA

Thomas E. Schlaepfer, MD

University of Bonn
Bonn, Germany

Stephen M. Stahl, MD, PhD

University of California, San Diego
La Jolla, California

Norman Sussman, MD, DFAPA

New York University Medical School
New York, NY

Karen Dineen Wagner, MD, PhD

The University of Texas Medical Branch
Galveston, TX

Herman G.M. Westenberg, MD

University Hospital Utrecht
Utrecht, The Netherlands

Stuart C. Yudofsky, MD

Baylor College of Medicine
Houston, TX

MBL COMMUNICATIONS Corporate Staff

CEO & PUBLISHER

Darren L. Brodeur

ASSOCIATE PUBLISHER

Elizabeth Katz

MANAGING EDITOR

Christopher Naccari

SENIOR EDITOR

Deborah Hughes

DEPUTY SENIOR EDITOR

José R. Ralat

ACQUISITIONS EDITOR

Lisa Arrington

ASSISTANT ACQUISITIONS EDITOR

Eileen S. Seligman

ASSISTANT EDITOR

Emil J. Ross

EDITORIAL ASSISTANT

Shelley Wong

PRODUCTION MANAGER

Lila Moses

GRAPHIC DESIGNER

Anthony J. Korsak

CONTROLLER

John Spano

NATIONAL ACCOUNT MANAGER

Kelly J. Staley

INFORMATION TECHNOLOGY

Greg Taube

OFFICE MANAGER

Claudette Crawford

OFFICE ASSISTANT

Manuel Pavón

CORPORATION COUNSEL

Lawrence Ross, Esq.

Bressler, Amery, and Ross

EDITORIAL MISSION

CNS Spectrums' editorial mission is to address relevant neuropsychiatric topics, including the prevalence of comorbid diseases among patients, and original research and reports that emphasize the profound diagnostic and physiologic connections made within the neurologic and psychiatric fields. The journal's goal is to serve as a resource to psychiatrists and neurologists seeking to understand and treat disturbances of cognition, emotion, and behavior as a direct consequence of central nervous system disease, illness, or trauma.

CNS SPECTRUMS®

The International Journal of Neuropsychiatric Medicine

Table of Contents

December 2003

Volume 8 - Number 12 - Supplement 3

5 Introduction

By David L. Dunner, MD, FACP

6 Treatment Considerations for Anxiety in the Elderly

By Eric J. Lenze, MD, Bruce G. Pollock, MD, PhD, M. Katherine Shear, MD, Benoit H. Mulsant, MD, Ashok Bharucha, MD, and Charles F. Reynolds III, MD

14 Treatment Considerations for Depression in the Elderly

By David L. Dunner, MD, FACP

20 Medically Unexplained Physical Symptoms: Toward an Alternative Paradigm for Diagnosis and Treatment

By Christos A. Ballas, MD, and Jeffrey P. Staab, MD

27 Achieving Long-Term Optimal Outcomes in Geriatric Depression and Anxiety

By Benoit H. Mulsant, MD, Ellen Whyte, MD, Eric J. Lenze, MD, Francis Lotrich, MD, PhD, Jordan F. Karp, MD, Bruce G. Pollock, MD, PhD, and Charles F. Reynolds III, MD

35 Quality of Life in Geriatric Patients with Mood and Anxiety Disorders

By Rachel E. Maddux, BA, Katia K. Delrahim, BA, and Mark H. Rapaport, MD

48 Adherence to Treatment for Geriatric Depression and Anxiety

By Julie Loebach Wetherell, PhD, and Jürgen Unützer, MD, MPH

CNS Spectrums is an *Index Medicus* journal and is available on MEDLINE under the citation *CNS Spectr.*

It is also indexed by DIALOG, EMBASE/Excerpta Medica, OVID, Lexis-Nexis, and SilverPlatter.

CNS Spectrums®

(ISSN 1092-8529)

is published monthly by MBL Communications, Inc. 333 Hudson Street, 7th Floor New York, NY 10013

One year subscription rates:

domestic \$120;

foreign \$185;

in-training \$75.

For subscriptions, Fax: 212-328-0600

Web site: www.cnsspectrums.com

For editorial inquiries:

dh@mbllcommunications.com

Postmaster:

Send address changes to

CNS Spectrums

c/o PPS Medical Marketing Group

264 Passaic Avenue

Fairfield, NJ 07004-2595

Opinions and views expressed by authors are their own and do not necessarily reflect the views of the publisher, MBL Communications, Inc., or the editorial advisory board.

CNS Spectrums® is a registered trademark of **CNS Spectrums, LLC**, New York, NY.

Permission to reproduce articles in whole or in part must be obtained in writing from the publisher.

MBL
communications

Copyright ©2003 by MBL Communications, Inc. All rights reserved.

Printed in the United States.